Merck & Co. and Eisai have to deal with the reality that yet another phase 3 trial of their combination of Keytruda and ...

Following the news of two lecanemab-related deaths reported on the eve of the Clinical Trials on Alzheimer’s Disease (CTAD) 2022 conference, Eisai has now presented the full results from its ...

but Biogen and Eisai's upbeat assessment of the study has already been hailed by the Alzheimer's Association in the US, which said they are "the most encouraging results in clinical trials ...